Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma

Atypical response patterns following immune checkpoint blockade (ICB) in Hodgkin lymphoma (HL) led to the concept of continuation of treatment beyond progression (TBP); however, the longitudinal benefit of this approach is unclear. We therefore performed a retrospective analysis of 64 patients treat...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncologist
Asıl Yazarlar: Merryman, Reid W., Carreau, Nicole A., Advani, Ranjana H., Spinner, Michael A., Herrera, Alex F., Chen, Robert, Tomassetti, Sarah, Ramchandren, Radhakrishnan, Hamid, Muhammad, Assouline, Sarit, Santiago, Raoul, Wagner‐Johnston, Nina, Paul, Suman, Svoboda, Jakub, Bair, Steven M., Barta, Stefan K., Liu, Yang, Nathan, Sunita, Karmali, Reem, Burkart, Madelyn, Torka, Pallawi, David, Kevin A., Wei, Catherine, Lansigan, Frederick, Emery, Lukas, Persky, Daniel, Smith, Sonali M., Godfrey, James, Chavez, Julio, Cohen, Jonathan B., Troxel, Andrea B., Diefenbach, Catherine, Armand, Philippe
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley & Sons, Inc. 2020
Konular:
Brief Communications
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7288660/
https://ncbi.nlm.nih.gov/pubmed/32275786
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0040
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller